Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18517108 | 0.86 | HCAR2 (0.32) | ESR1ESR2HCAR2 | |
| SCHEMBL19633737 | 0.85 | CNR2 (0.38) | ESR1ESR2CNR2CNR1 | |
| SCHEMBL19633847 | 0.85 | CNR2 (0.38) | ESR1ESR2CNR2CNR1 | |
| SCHEMBL22752359 | 0.82 | TLR8 (0.35) | ESR1ESR2TLR8 | |
| SCHEMBL22752554 | 0.82 | KDM4E (0.36) | HCAR2 | |
| SCHEMBL22752535 | 0.82 | TLR8 (0.33) | TLR8 | |
| SCHEMBL18516838 | 0.79 | CNR2 (0.36) | ESR1ESR2CNR2CNR1HCAR2 | |
| SCHEMBL22169010 | 0.79 | CYP19A1 (0.36) | ESR1ESR2 | |
| SCHEMBL18856535 | 0.78 | SCN5A (0.35) | CNR2TLR8CNR1 | |
| SCHEMBL23142669 | 0.77 | CNR2 (0.37) | ESR1ESR2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | ESR1 4844/4885ESR2 4812/4885CNR2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.